Theravance Biopharma Inc
TBPH
NASDAQ·Healthcare·Biotechnology·Mkt cap $885.2M
$17.08
▲ 0.00%
P/E
16.85
Mkt Cap
$885.2M
52-Wk Range
$13.08–$21.03
52-Week Range
$13.08 - $21.03
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 22.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary nebulized delivery technology for respiratory treatments enabling once-daily dosing convenience
- Gut-selective JAK inhibitor platform reducing systemic side effects while targeting inflammatory bowel diseases
- Strategic partnerships with major pharmaceutical companies (Pfizer, Janssen, Takeda) providing development support and commercial distribution capabilities
- Diversified pipeline across multiple high-prevalence therapeutic areas with significant unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Revenue decline expected
Expanding YUPELRI market penetration in COPD treatment as awareness grows among respiratory specialists
Value
Trading at 0.3x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Stable
+4.8% over 3m
Quality
Excellent
High-growth business (35% revenue growth, 89% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying TBPH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.11 vs $0.07 consensus (-251.7% surprise). Revenue of $20.7M vs $22.5M expected (-7.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-251.7%
Revenue trend · last 8Q
—
+7%
+6%
+84%
+19%
+145%
+15%
-21%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$16.9M
$18.8M
$15.4M
$26.2M
$20.0M
$45.9M
$17.7M
$20.7M
Margins · last 8Q
Gross
-78.4%
Operating
-45.6%
Profit
-28.4%
Wall Street consensus
4 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 7, 2026
vs Industry
How TBPH stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related